BCL2 and fibrolamellar hepatocellular carcinoma: We identified upregulation of the prosurvival Bcl-2 family protein, BCL-XL, in resistant FLC models and demonstrated that modulating apoptotic priming with the BCL-XL targeting agent navitoclax resulted in synergy with irinotecan, particularly in resistant FLC models (14).